Verily introduces Lightpath, a personalized, AI-powered chronic care solution, backed by deep clinical expertise

San Bruno, CA - June 11, 2024 - Today, Verily, Alphabet’s precision health company, announced its plans for Lightpath¹, a personalized chronic care solution designed to meet the changing needs of health plans and their members. The first offering, Lightpath Metabolic, will help members with cardiometabolic diseases achieve and maintain their health goals. It is planned to be available for open enrollment in early 2026. 

Lightpath Metabolic is a next generation solution that will build on the clinical, data, and user expertise that drives Onduo, Verily’s virtual care management solution. Lightpath Metabolic will offer modular programs to provide a comprehensive and flexible care solution that supports an expanded set of conditions and can be adjusted to meet members’ health needs. As clinically indicated, members will be able to move from intensive programs to less intensive programs, with ongoing monitoring to move members back as needed. The programs include:

• Metabolic Intensive — a program for the management of type 1 diabetes, type 2 diabetes, hypertension, comorbid obesity, and/or hyperlipidemia. 
• Weight Loss Intensive — a clinically-guided, weight loss program that includes the labeled use of anti-obesity medications.²
• Metabolic Improvement — a program for diabetes prevention, hypertension, and well-managed metabolic conditions. 
• Metabolic Achievement — a long-term monitoring and support program for members who have achieved their health goals. 

The solution will be built on Verily’s precision health platform, and will continuously integrate data from health records, connected devices, and other care touch points to deliver personalized pathways, suggestions, and nudges to members. It will pair technology with health coaches and an advanced licensed clinical team that includes endocrinologists, pharmacists, primary care physicians, nurses, and registered dietitians.³ Members will be able to receive care through telemedicine visits and have medications reviewed and optimized where clinically indicated.²

“Lightpath demonstrates our commitment to supporting people living with chronic conditions, as the care landscapes quickly evolve,” said Myoung Cha, Chief Product Officer at Verily. “By applying today’s latest technology, combined with clinical expertise and a great user experience, we aim to help members achieve their goals and live healthier lives.”

Lightpath will apply recent AI advancements to support both members and clinicians. Members will have access to an AI helper, designed to inform personal pathways, monitor behavior, and support engagement. An AI assistant will be available for clinical staff. 

“To truly impact care, we must understand our patients more precisely and tailor experiences based on their unique needs and circumstances,” said Vindell Washington, MD, MS Chief Clinical Officer and Head of Verily’s Center of Excellence for Health Equity. “Through Lightpath, we will incorporate the many factors that contribute to health in order to deliver more personalized and equitable care.”

Since 2018, Verily has offered Onduo, a virtual care management solution that provides personalized support for members living with diabetes and other chronic conditions. A peer-reviewed, 4-month study⁴ of Onduo for type 2 diabetes with chronic care model use showed significant glycemic improvements, along with significant improvements in comorbidity biomarkers, such as systolic blood pressure, total cholesterol and weight. Verily aims for customers using Onduo to be able to migrate to Lightpath Metabolic in late 2025.

Cardiometabolic conditions are on the rise, and present a significant burden to health plans and their members — impacting quality of life and productivity, while driving increased cost of care. Meanwhile the treatment landscape is rapidly changing with the growing use of GLP-1 medications and continuous glucose monitoring, presenting the need to effectively manage these interventions. Lightpath will help members receive personalized care while empowering them to proactively manage their health.

About Verily

Verily is an Alphabet health technology company focused on research, care, and health financing to deliver on the promise of precision health and help people live healthier lives. We are uniquely positioned at the intersection of technology, data science, and healthcare to create tools to accelerate evidence generation, products to enable more personalized care, and approaches to make costs more predictable. For more information about Verily Lightpath, please visit: verily.com/lightpath-metabolic.

Forward-looking statements

We believe that it is important to communicate our product direction to customers, including through forward-looking statements that may involve uncertainties. The information shared in this release is not a legal or other obligation to deliver any product functionality, capabilities, or timeframes, and the features described here are subject to change.

References

1. Verily Life Sciences LLC (“Verily”) offers virtual care management programs for eligible individuals, as further described in these materials and at verily.com. Verily collaborates with Onduo Management Services LLC (“OMS”), Onduo LLC, and a network of affiliated Professional Entities to offer the services. These services are meant to be used in conjunction with regular in-person clinical services and not intended to replace routine primary care.
2. May not be available in all 50 states.
3. Statements related to Rx treatments are for members receiving telemedicine services with licensed health care providers through Onduo P.C.
4. Majithia AR, Kusiak CM, Improved Glycemic Outcomes in Adults With Type 2 Diabetes Participating in a Continuous Glucose Monitor Driven Virtual Diabetes Clinic: Prospective Trial. J Med Internet Res. 2020;22(8):e21778. doi:10.2196/21778 n=55; 60 days intermittent CGM wear, n=43